Tobira Therapeutics Inc. Reports Encouraging Pharmacokinetic, Bioavailability and Safety Results from Studies of Cenicriviroc

MANALAPAN, N.J. & BOSTON--(BUSINESS WIRE)--Tobira Therapeutics reported today that single-dose oral administration of cenicriviroc showed predictable pharmacokinetics, good oral bioavailability and no dose-limiting toxicity in both healthy human volunteers and animal models. Cenicriviroc (TBR-652) is a potent antagonist of both CCR5, a co-receptor required for HIV infection, and CCR2, a co-receptor that is prominently involved in a number of metabolic and cardiovascular diseases. Cenicriviroc is currently in Phase 2 clinical development for the treatment of individuals with HIV infection.